Literature DB >> 25057036

Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008.

P Elfving1, K Puolakka2, H Kautiainen3, L J Virta4, T Pohjolainen5, O Kaipiainen-Seppänen6.   

Abstract

The objectives of the study were to investigate mortality and causes of death in patients with recent-onset systemic lupus erythematosus (SLE) in Finland. Data for patients with SLE for the study were collected (2000-2007) from the nationwide register on decisions of special reimbursements for drugs, maintained by the Social Insurance Institution (SII) in Finland. Data on deaths of the patients were obtained from the official death certificate statistics of Statistics Finland until the end of 2008. Of the 566 incident SLE patients, median follow-up time was 5.4 (IQR 3.3, 7.1) years, and 30 patients (23 females, seven males) died in the years 2000 through 2008. Mean age at death was 67.8 ± 17.2 years for females and 62.3 ± 15.2 years for males. The 5-year survival rates were 94.8% (95%CI 92.0-96.6%) and 88.2% (95%CI 76.5-94.3%), respectively. The age- and sex-adjusted standardized mortality ratio was 1.48 (95%CI 1.01-2.12). Primary causes of death were cardiovascular diseases, malignancy and SLE itself. In conclusion, survival of the patients with SLE was inferior to that of the general population. Cardiovascular diseases were responsible for 37% of deaths.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Systemic lupus erythematosus; cardiovascular diseases; causes of death; mortality; survival

Mesh:

Year:  2014        PMID: 25057036     DOI: 10.1177/0961203314543919

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

2.  Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients.

Authors:  Cécile M Yelnik; Monica Richey; Virginia Haiduc; Sotiria Everett; Meng Zhang; Doruk Erkan
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-26       Impact factor: 4.794

Review 3.  Mortality in Systemic Lupus Erythematosus: an Updated Review.

Authors:  César E Fors Nieves; Peter M Izmirly
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

4.  Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality.

Authors:  Alimohammad Fatemi; Mohammad Matinfar; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2016-12-23       Impact factor: 2.980

5.  Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort.

Authors:  Xuebing Feng; Wenyou Pan; Lin Liu; Min Wu; Fuwan Ding; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Lingyun Sun
Journal:  PLoS One       Date:  2016-12-28       Impact factor: 3.240

Review 6.  Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases.

Authors:  Aikaterini Arida; Athanasios D Protogerou; George D Kitas; Petros P Sfikakis
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

7.  Age-adjusted Charlson Comorbidity Index scores predict major adverse cardiovascular events and all-cause mortality among systemic lupus erythematosus patients.

Authors:  Mei-Hua Chuang; Tzyy-Ling Chuang; Kuang-Yung Huang; Yuh-Feng Wang
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Jul-Sep

8.  Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis.

Authors:  Oh Chan Kwon; Jung Hwan Park; Yong-Beom Park; Min-Chan Park
Journal:  Arthritis Res Ther       Date:  2020-07-31       Impact factor: 5.156

9.  Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation.

Authors:  Tingting Weng; Jingjing Huang; Eric J Wagner; Junsuk Ko; Minghua Wu; Nancy E Wareing; Yu Xiang; Ning-Yuan Chen; Ping Ji; Jose G Molina; Kelly A Volcik; Leng Han; Maureen D Mayes; Michael R Blackburn; Shervin Assassi
Journal:  J Exp Med       Date:  2020-02-03       Impact factor: 14.307

10.  Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls.

Authors:  Irene E M Bultink; Frank de Vries; Ronald F van Vollenhoven; Arief Lalmohamed
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.